Impact of complete surgical staging on survival of patients with early-stage (FIGO I or II) ovarian cancer: Data from the Cote d'Or Registry of Gynecological Cancers from 1998 to 2015.

[1]  F. Marmé,et al.  Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. , 2019, The New England journal of medicine.

[2]  B. Ataseven,et al.  How to manage lymph nodes in ovarian cancer , 2019, Cancer.

[3]  F. Ghezzi,et al.  Sentinel-Node Biopsy in Early Stage Ovarian Cancer: Preliminary Results of a Prospective Multicentre Study (SELLY). , 2019, American journal of obstetrics and gynecology.

[4]  B. Monk,et al.  Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. , 2019, The New England journal of medicine.

[5]  Danielle M. Enserro,et al.  Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Timmerman,et al.  ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  P. Collinet,et al.  [Surgery in early-stage ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa]. , 2019, Gynecologie, obstetrique, fertilite & senologie.

[8]  C. Genestie,et al.  Staging surgery in early-stage ovarian mucinous tumors according to expansile and infiltrative types , 2017, Gynecologic oncology reports.

[9]  M. van der Aa,et al.  The impact of lymph node dissection and adjuvant chemotherapy on survival: A nationwide cohort study of patients with clinical early-stage ovarian cancer. , 2016, European journal of cancer.

[10]  C. Fotopoulou,et al.  Incidence of Lymph Node Metastases in Apparent Early-Stage Low-Grade Epithelial Ovarian Cancer: A Comprehensive Review , 2016, International Journal of Gynecologic Cancer.

[11]  H. Kitchener,et al.  Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. , 2015, The Cochrane database of systematic reviews.

[12]  Jacobus Pfisterer,et al.  Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial , 2015, The Lancet. Oncology.

[13]  Y. Minagawa,et al.  Clinical impact of systematic pelvic and para-aortic lymphadenectomy for pT1 and pT2 ovarian cancer: a retrospective survey by the Sankai Gynecology Study Group , 2013, International Journal of Clinical Oncology.

[14]  P. Neven,et al.  Primary invasive mucinous ovarian carcinoma of the intestinal type: importance of the expansile versus infiltrative type in predicting recurrence and lymph node metastases. , 2013, European journal of cancer.

[15]  M. Coleman,et al.  Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership. , 2012, Gynecologic oncology.

[16]  F. Raspagliesi,et al.  Systematic Para-aortic and Pelvic Lymphadenectomy in Early Stage Epithelial Ovarian Cancer: A Prospective Study , 2012, Annals of Surgical Oncology.

[17]  M. Irahara,et al.  The impact of systematic para‐aortic and pelvic lymphadenectomy on survival in patients with optimally debulked ovarian cancer , 2010, The journal of obstetrics and gynaecology research.

[18]  J. Galon,et al.  Implications immunologiques potentielles du curage ganglionnaire : Exemple du cancer colorectal , 2008 .

[19]  C. Tropé,et al.  Primary surgery for ovarian cancer. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[20]  V. Torri,et al.  Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis , 2006, British Journal of Cancer.

[21]  N. Hacker,et al.  Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. , 2005, Journal of the National Cancer Institute.

[22]  B. Hagen,et al.  THE EFFECT OF CENTRALIZATION OF PRIMARY SURGERY ON SURVIVAL IN OVARIAN CANCER PATIENTS , 2003, International Journal of Gynecologic Cancer.

[23]  M. Franchi,et al.  Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. , 2003, Journal of the National Cancer Institute.

[24]  E. Trimble,et al.  Patterns of care for women with ovarian cancer in the United States. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Gultekin,et al.  Occult metastasis in early ovarian cancers: risk factors and associated prognosis. , 2007, American journal of obstetrics and gynecology.